| Similar Articles |
|---|
 |
The Motley Fool
May 7, 2007
Mike Havrilla |
Advanced Life Makes Progress After positive data in an anthrax study, Advanced Life Sciences' potential antibiotic cethromycin has been granted FDA Orphan Drug status for this indication. Investors, take note.   |
BusinessWeek
April 2, 2007
Gene G. Marcial |
Advanced Life Sciences Is Advancing On Anthrax Investors who stuck with Advanced Life Sciences even after it delayed completion of Phase 3 clinical trials on cethromycin felt rewarded when the Food & Drug Administration granted it "Orphan Drug" designation. |
The Motley Fool
June 14, 2005
Tom Taulli |
Morgan, Minus Purcell Amid turmoil, Morgan Stanley's CEO bails out. Morgan indicated that its earnings will fall anywhere from 15% to 20% lower than last year's, to between $0.88 cents and $0.94 cents a share. |
Registered Rep.
October 20, 2010
Kristen French |
Morgan Stanley Q3 Earnings Dive 67%, Wealth Management Is Most Profitable Division Morgan Stanley Smith Barney dunked into the red in the third quarter, with earnings falling 67 percent to 5 cents a share, due to a sharp decline in the firm's institutional securities business. |
The Motley Fool
December 17, 2008
Morgan Housel |
No Good News for Morgan Stanley If Morgan Stanley really is retreating from the old investment banking model, then what's next for the investment-bank-turned-bank-holding-company? |
Registered Rep.
October 29, 2002
Rick Weinberg |
Morgan Stanley Opposes Fine Following the New York Attorney General's investigation of Merrill Lynch's research practices, the firm was fined $100 million. The attorney general's office is in the midst of an ongoing investigation of other firms, including Morgan Stanley, which is fighting back. |
The Motley Fool
December 20, 2005
Stephen D. Simpson |
Will Morgan Stanley Come Back? Investors who thought that the return of John Mack to Morgan Stanley would mean instant and glorious change might be feeling a bit disappointed about now. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Biotech Prospects for a Sizzling Summer Consider these biotech stocks to make your portfolio sizzle this summer. Advanced Life Sciences... Depomed... Theravance... etc. |
The Motley Fool
September 21, 2005
Stephen D. Simpson |
Morgan Moves On In the wake of a high-profile battle at the top, Morgan Stanley tries to get back to the business of business. But is the board up to snuff and concerned with protecting regular shareholders? |
The Motley Fool
June 22, 2004
Roger Nusbaum |
The House of Morgan Stanley Morgan Stanley has had its fair share of wrongdoing, but despite its warts, the brokerage firm should continue to thrive. |
Registered Rep.
March 8, 2012
Kristen French |
Due Diligence: Morgan Stanley Advisors Paid to Put Clients in New Amex Credit Card Morgan Stanley Smith Barney financial advisors and client service associates will get a "small" amount of compensation for the administrative process of handling card sign up. |
The Motley Fool
September 30, 2010
Tim Hanson |
Today's Buy Opportunity: T. Rowe Price Group Why the Fool's buying shares of T. Rowe Price. |
Chemistry World
May 6, 2014
Andy Extance |
WHO raises alarm on deadly bacteria The World Health Organization has warned antibiotic resistant bacteria could bring a nightmarish future, where seemingly trivial scrapes turn lethal, and currently routine operations become too risky to contemplate. |
The Motley Fool
June 19, 2008
Morgan Housel |
Morgan Stanley Stumbles In light of Morgan Stanley's dismal earnings release, let's get one thing straight: It could have been much, much worse. |
The Motley Fool
December 28, 2005
Michael D. Leibert |
Like the Funds? Love the Advisor! Investors in T. Rowe Price funds do well, but investors in the advisor do even better. |
The Motley Fool
March 22, 2006
Stephen D. Simpson |
Morgan Stanley Trades Up The bottom line for investors: in an environment where industrywide valuations are creeping higher, there are better bank ideas out there. |
BusinessWeek
April 19, 2004
Gene G. Marcial |
Morgan Stanley Is Going For A Song Morgan Stanley's stock is still at a big discount to its peers -- trading below historic levels based on price-earnings, price-to-book, and price-to-sales ratios. |
The Motley Fool
September 20, 2007
Matt Koppenheffer |
What Has Lazard Been Up To? The investment-banking specialist has been aggressively growing its business over the past year. |
The Motley Fool
October 21, 2009
Morgan Housel |
Morgan Stanley's Back in the Game It's good news that Morgan Stanley's trading unit is firing on all cylinders. But the idea of a Wall Street arms race to profitability should please no one. |
The Motley Fool
July 26, 2011
Rich Smith |
Does Soros Know Something You Don't? George Soros, the man who sank the British Pound in 1992, announces he will close his flagship Quantum Endowment Fund to new investors, cash out outside investors, and run Quantum exclusively as a wealth-management vessel for his family. |
Wall Street & Technology
November 17, 2003 |
Vendor's Audition for T. Rowe Show Frustrated with the slow-moving request-for-proposal process, T. Rowe has developed an alternative method for selecting vendors. |
Registered Rep.
May 1, 2005
Glenn Curtis |
The Purcell Discount Hovering at a recent $51.73 --- down from its all-time highs of $110 a share --- are Morgan Stanley common shares a buy? |
The Motley Fool
August 10, 2010
Andrew Bond |
T. Rowe Price: Strengths, Weaknesses, Opportunities, Threats A look inside the business of T. Rowe Price. |
BusinessWeek
January 17, 2005
Justin Hibbard |
Morgan Stanley: No Stars -- And Lots Of Top Tech IPOs The firm has perfected the long-term team approach to landing high-quality clients that are ready to go public. |
BusinessWeek
July 28, 2003
Roberts & Clifford |
Morgan Stanley: What Great Wall? In a joint venture, the big U.S. bank breaks into China's financial sector |
Registered Rep.
June 1, 2005
Kristen French |
Gimme Back My Ad! Morgan Stanley has directed key media outlets to contact its ad agency if they write "objectionable" stories about the company, and if they can't get through in time, to yank its ads for at least 48 hours. |
The Motley Fool
September 27, 2007
Amanda B. Kish |
The Best Funds From T. Rowe Price: Part 1 A closer look at these T. Rowe Price funds: T. Rowe Price Personal Growth Fund... T. Rowe Price Spectrum Growth Fund... |
Registered Rep.
April 21, 2010
Jerry Gleeson |
Morgan Stanley Profits Rise, Advisor Count Flat Morgan Stanley on Wednesday reported higher-than-expected revenues and profits in the first quarter, lifted by its acquisition last spring of Smith Barney and by higher fixed income. |
Registered Rep.
April 27, 2004
Will Leitch |
Morgan, Restructuring Its Asset Management Unit, Closes 13 Funds Morgan Stanley announced it was dissolving 13 of its proprietary funds as part of its attempts to "streamline" its business for affluent investors. |
The Motley Fool
September 21, 2010
Andrew Bond |
Give Yourself a Home-Field Investing Edge Look close to home in your own state for great investing ideas. |
AskMen.com
Harold Russell |
The Lowdown On Superbugs The overuse and misuse of antibiotics has led to the development of resistant strains of bacteria, commonly referred to as superbugs. |
Registered Rep.
November 12, 2003 |
Morgan Stanley Launches Conflict-of-Interest Probe Morgan Stanley has announced it is conducting an in-house conflict-of-interest probe. |
Entrepreneur
March 2006
Dian Vujovich |
Some Like it Hot Spice up your portfolio with a Latin American fund. But do it in small doses. |
Registered Rep.
May 1, 2005
Will Leitch |
So They've Got That Going for Them...Which Is Nice For all the problems it's been having in the last several months, Morgan Stanley can hang its hat on this good news: It is now the largest securities firm in the country. |
American Family Physician
September 15, 2006 |
When Antibiotics Can Help A consumer's guide: What are antibiotics?... How do antibiotics work?... What is antibiotic resistance?... How can I prevent antibiotic resistance?... |
Wall Street & Technology
June 4, 2004
Jessica Pallay |
A Penny Saved Is a Penny Earned Michael Goff prepares T. Rowe Price for the economic upturn with a long-term IT strategy. |
The Motley Fool
March 20, 2008
Morgan Housel |
Morgan Stanley's Traders Score Big Morgan Stanley became the latest of the major investment banks to report better-than-expected earnings this week, sweetening some of the market's viciously sour mood. |
